Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation ; A Binational Population-Based Study

Title: Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation ; A Binational Population-Based Study
Authors: Lam, Dickson; Scaria, Anish; Andrade, Jason; Badve, Sunil V.; Birks, Peter; Bota, Sarah E.; Campain, Anna; Djurdjev, Ognjenka; Garg, Amit X.; Harel, Ziv; Hemmelgarn, Brenda; Hockham, Carinna; James, Matthew T.; Jardine, Meg J.; Levin, Adeera; McArthur, Eric; Ravani, Pietro; Shao, Selena; Sood, Manish M.; Tan, Zhi; Tangri, Navdeep; Whitlock, Reid; Gallagher, Martin; Jun, Min; Ha, Jeffrey T.
Contributors: National Health and Medical Research Council
Source: Kidney360 ; volume 6, issue 9, page 1510-1521 ; ISSN 2641-7650
Publisher Information: Ovid Technologies (Wolters Kluwer Health)
Publication Year: 2025
Description: Key Points This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and
Document Type: article in journal/newspaper
Language: English
DOI: 10.34067/kid.0000000809
DOI: 10.34067/KID.0000000809
Availability: https://doi.org/10.34067/kid.0000000809; https://journals.lww.com/10.34067/KID.0000000809
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.17014CEC
Database: BASE